Anti-(candida Heat-shock Protein Hsp 90) (human Monoclonal Hsp90mab Fragment) Uses, Dosage, Side Effects and more
Anti-(candida Heat-shock Protein Hsp 90) (human Monoclonal Hsp90mab Fragment) is under investigation in clinical trial NCT00217815 (Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer).
| Attribute | Details |
|---|---|
| Trade Name | Anti-(candida Heat-shock Protein Hsp 90) (human Monoclonal Hsp90mab Fragment) |
| Generic | Efungumab |
| Efungumab Other Names | Efungumab, Hsp-90mab, Hsp90mab, Immunoglobulin, anti-(candida heat-shock protein hsp 90) (human monoclonal hsp90mab fragment), Mycograb |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
